| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Tuesday, June 29, 2021 7:02:03 AM
Big gap and lot of money to be spent on continuation of just for hope. Hope everything comes to fruition in the long but like you said it a ways away.
Recent NTLA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 11:49:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 11:36:17 AM
- Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates • GlobeNewswire Inc. • 05/11/2026 11:30:00 AM
- Intellia Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/05/2026 11:30:00 AM
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:30:29 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:23:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:16:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:10:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/29/2026 09:28:35 PM
- Intellia Therapeutics Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/27/2026 09:19:08 PM
- Intellia Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 04/27/2026 08:01:00 PM
- Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data • IH Market News • 04/27/2026 03:20:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:13:36 PM
- Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 • GlobeNewswire Inc. • 04/24/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:16:24 PM
- The Credibility Filter Wall Street Uses to Sort Biotech Winners • GlobeNewswire Inc. • 04/08/2026 01:15:00 PM
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2026 08:05:00 PM
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/06/2026 09:01:00 PM
